Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Neoplasia ; 23(7): 676-691, 2021 07.
Article in English | MEDLINE | ID: mdl-34139452

ABSTRACT

The blood-brain barrier (BBB) is a major anatomical and physiological barrier limiting the passage of drugs into brain. Central nervous system tumors can impair the BBB by changing the tumor microenvironment leading to the formation of a leaky barrier, known as the blood-tumor barrier (BTB). Despite the change in integrity, the BTB remains effective in preventing delivery of chemotherapy into brain tumors. Focused ultrasound is a unique noninvasive technique that can transiently disrupt the BBB and increase accumulation of drugs within targeted areas of the brain. Herein, we summarize the current understanding of different types of targeted ultrasound mediated BBB/BTB disruption techniques. We also discuss influence of the tumor microenvironment on BBB opening, as well as the role of immunological response following disruption. Lastly, we highlight the gaps between evaluation of the parameters governing opening of the BBB/BTB. A deeper understanding of physical opening of the BBB/BTB and the biological effects following disruption can potentially enhance treatment strategies for patients with brain tumors.


Subject(s)
Blood-Brain Barrier/metabolism , Blood-Brain Barrier/radiation effects , Brain Neoplasms/metabolism , Drug Delivery Systems , Tumor Microenvironment/radiation effects , Ultrasonic Waves , Animals , Biological Transport/radiation effects , Biological Variation, Population , Brain Neoplasms/drug therapy , Brain Neoplasms/etiology , Brain Neoplasms/pathology , Disease Models, Animal , High-Intensity Focused Ultrasound Ablation/adverse effects , High-Intensity Focused Ultrasound Ablation/methods , Humans , Neoplasm Metastasis , Permeability/radiation effects , Treatment Outcome , Tumor Microenvironment/drug effects , Tumor Microenvironment/immunology , Ultrasonic Therapy
2.
J Biol Chem ; 276(42): 38934-9, 2001 Oct 19.
Article in English | MEDLINE | ID: mdl-11495904

ABSTRACT

Selective modulators of gamma-aminobutyric acid, type A (GABA(A)) receptors containing alpha(4) subunits may provide new treatments for epilepsy and premenstrual syndrome. Using mouse L(-tk) cells, we stably expressed the native GABA(A) receptor subunit combinations alpha(3)beta(3)gamma(2,) alpha(4)beta(3)gamma(2), and, for the first time, alpha(4)beta(3)delta and characterized their properties using a novel fluorescence resonance energy transfer assay of GABA-evoked depolarizations. GABA evoked concentration-dependent decreases in fluorescence resonance energy transfer that were blocked by GABA(A) receptor antagonists and, for alpha(3)beta(3)gamma(2) and alpha(4)beta(3)gamma(2) receptors, modulated by benzodiazepines with the expected subtype specificity. When combined with alpha(4) and beta(3), delta subunits, compared with gamma(2), conferred greater sensitivity to the agonists GABA, 4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridin-3-ol (THIP), and muscimol and greater maximal efficacy to THIP. alpha(4)beta(3)delta responses were markedly modulated by steroids and anesthetics. Alphaxalone, pentobarbital, and pregnanolone were all 3-7-fold more efficacious at alpha(4)beta(3)delta compared with alpha(4)beta(3)gamma(2.) The fluorescence technique used in this study has proven valuable for extensive characterization of a novel GABA(A) receptor. For GABA(A) receptors containing alpha(4) subunits, our experiments reveal that inclusion of delta instead of gamma(2) subunits can increase the affinity and in some cases the efficacy of agonists and can increase the efficacy of allosteric modulators. Pregnanolone was a particularly efficacious modulator of alpha(4)beta(3)delta receptors, consistent with a central role for this subunit combination in premenstrual syndrome.


Subject(s)
Membrane Potentials , Receptors, GABA-A/chemistry , Spectrometry, Fluorescence/methods , Animals , Benzodiazepines/pharmacology , Cell Line , Dose-Response Relationship, Drug , Humans , Mice , Models, Biological , Muscimol/pharmacology , Pentobarbital/pharmacology , Pregnanediones/pharmacology , Pregnanolone/pharmacology , Protein Binding , Protein Conformation , Time Factors , Transfection , gamma-Aminobutyric Acid/metabolism
3.
Biochem J ; 352 Pt 3: 929-33, 2000 Dec 15.
Article in English | MEDLINE | ID: mdl-11104705

ABSTRACT

Adenophostin A, the most potent known agonist of inositol 1,4, 5-trisphosphate (InsP(3)) receptors, stimulated (45)Ca(2+) release from the intracellular stores of permeabilized hepatocytes. The concentration of adenophostin A causing the half-maximal effect (EC(50)) was 7.1+/-0.5 nM, whereas the EC(50) for InsP(3) was 177+/-26 nM; both responses were positively co-operative. In rapid superfusion analyses of (45)Ca(2+) release from the intracellular stores of immobilized hepatocytes, maximal concentrations of adenophostin A or InsP(3) evoked indistinguishable patterns of Ca(2+) release. The Ca(2+) release evoked by both agonists peaked at the same maximal rate after about 375 ms and the activity of the receptors then decayed to a stable, partially (60%) inactivated state with a half-time (t(1/2)) of 318+/-29 ms for adenophostin A and 321+/-22 ms for InsP(3). Dissociation rates were measured by recording rates of InsP(3)-receptor channel closure after rapid removal of agonist. The rate of adenophostin A dissociation (t(1/2), 840+/-195 ms) was only 2-fold slower than that of InsP(3) (t(1/2), 436+/-48 ms). We conclude that slow dissociation of adenophostin A from InsP(3) receptors does not underlie either its high-affinity binding or the reported differences in the Ca(2+) signals evoked by InsP(3) and adenophostin A in intact cells.


Subject(s)
Adenosine/analogs & derivatives , Adenosine/pharmacology , Calcium Channel Agonists/pharmacology , Calcium Channels/metabolism , Calcium Signaling/drug effects , Ion Channel Gating/drug effects , Receptors, Cytoplasmic and Nuclear/metabolism , Adenosine/metabolism , Animals , Calcium/metabolism , Calcium/pharmacology , Calcium Channel Agonists/metabolism , Cell Membrane Permeability , Hepatocytes/drug effects , Hepatocytes/metabolism , Inositol 1,4,5-Trisphosphate/metabolism , Inositol 1,4,5-Trisphosphate/pharmacology , Inositol 1,4,5-Trisphosphate Receptors , Kinetics , Male , Protein Binding , Rats , Rats, Wistar
4.
Biochem J ; 345 Pt 2: 357-63, 2000 Jan 15.
Article in English | MEDLINE | ID: mdl-10620513

ABSTRACT

InsP(3) binding to type-1, but not type-3, InsP(3) receptors is inhibited by calmodulin in a Ca(2+)-independent fashion [Cardy and Taylor (1998) Biochem. J. 334, 447-455], and Ca(2+) mobilization by type-1 InsP(3) receptors of cerebellum is inhibited by calmodulin [Patel, Morris, Adkins, O'Beirne and Taylor (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 11627-11632]. Using cell types expressing predominantly type-1, -2 or -3 InsP(3) receptors, we show that InsP(3)-evoked Ca(2+) mobilization from each is similarly inhibited by calmodulin. In SH-SY5Y cells, which express largely type-1 receptors, calmodulin (IC(50) approximately 15 microM) inhibited InsP(3)-evoked Ca(2+) release only in the presence of Ca(2+). The inhibition was unaffected by calcineurin inhibitors. The effect of calmodulin did not result from enhanced metabolism of InsP(3) because calmodulin also decreased the sensitivity of the Ca(2+) stores to adenophostin A, a non-metabolizable InsP(3)-receptor agonist. Protein kinase A-catalysed phosphorylation of type-1 InsP(3) receptors was unaffected by Ca(2+)-calmodulin. Using a scintillation proximity assay to measure (125)I-calmodulin binding to glutathione S-transferase-fusion proteins, we identified two regions of the type-1 InsP(3) receptor (cyt1, residues -6 to 159; and cyt11, residues 1499-1649) that bound (125)I-calmodulin. The higher-affinity site (cyt11) was also photoaffinity labelled with N-hydroxysuccinimidyl-4-azidobenzoate (HSAB)-calmodulin. We speculate that Ca(2+)-independent binding of calmodulin to a site within the first 159 residues of the type-1 InsP(3) receptor inhibits InsP(3) binding and may thereby regulate the kinetics of Ca(2+) release. Ca(2+)-dependent inhibition of Ca(2+) release by calmodulin is mediated by a different site: it may reside on an accessory protein that associates with all three receptor subtypes, or Ca(2+)-calmodulin binding to a site lying between residues 1499 and 1649 of the type-1 receptor may inhibit Ca(2+) release from any tetrameric receptor that includes a type-1 subunit.


Subject(s)
Calcium Channels/drug effects , Calcium/metabolism , Calmodulin/pharmacology , Receptors, Cytoplasmic and Nuclear/drug effects , Adenosine/analogs & derivatives , Adenosine/pharmacology , Animals , Calcium Channels/classification , Calcium Channels/genetics , Calcium Channels/metabolism , Cell Membrane Permeability , Cerebellum/cytology , Cerebellum/metabolism , Cyclic AMP-Dependent Protein Kinases/metabolism , Humans , Inositol 1,4,5-Trisphosphate Receptors , Liver/cytology , Liver/metabolism , Phosphorylation , Protein Binding , Rats , Receptors, Cytoplasmic and Nuclear/classification , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Cytoplasmic and Nuclear/metabolism , Recombinant Fusion Proteins/drug effects , Recombinant Fusion Proteins/metabolism , Tumor Cells, Cultured
5.
Curr Biol ; 9(19): 1115-8, 1999 Oct 07.
Article in English | MEDLINE | ID: mdl-10531009

ABSTRACT

Ryanodine and inositol 1,4,5-trisphosphate (IP(3)) receptors - two related families of Ca(2+) channels responsible for release of Ca(2+) from intracellular stores [1] - are biphasically regulated by cytosolic Ca(2+) [2] [3] [4]. It is thought that the resulting positive feedback allows localised Ca(2+)-release events to propagate regeneratively, and that the negative feedback limits the amplitude of individual events [5] [6]. Stimulation of IP(3) receptors by Ca(2+) occurs through a Ca(2+)-binding site that becomes exposed only after IP(3) has bound to its receptor [7] [8]. Here, we report that rapid inhibition of IP(3) receptors by Ca(2+) occurs only if the receptor has not bound IP(3). The IP(3) therefore switches its receptor from a state in which only an inhibitory Ca(2+)-binding site is accessible to one in which only a stimulatory site is available. This regulation ensures that Ca(2+) released by an active IP(3) receptor may rapidly inhibit its unliganded neighbours, but it cannot terminate the activity of a receptor with IP(3) bound. Such lateral inhibition, which is a universal feature of sensory systems where it improves contrast and dynamic range, may fulfil similar roles in intracellular Ca(2+) signalling by providing increased sensitivity to IP(3) and allowing rapid graded recruitment of IP(3) receptors.


Subject(s)
Calcium Channels/chemistry , Calcium Channels/metabolism , Calcium/metabolism , Receptors, Cytoplasmic and Nuclear/chemistry , Receptors, Cytoplasmic and Nuclear/metabolism , Animals , Calcium/pharmacology , Calcium Signaling , Cells, Cultured , Cytosol/metabolism , Inositol 1,4,5-Trisphosphate Receptors , Liver/metabolism , Rats , Time Factors
6.
Proc Natl Acad Sci U S A ; 94(21): 11627-32, 1997 Oct 14.
Article in English | MEDLINE | ID: mdl-9326661

ABSTRACT

The interactions between calmodulin, inositol 1,4,5-trisphosphate (InsP3), and pure cerebellar InsP3 receptors were characterized by using a scintillation proximity assay. In the absence of Ca2+, 125I-labeled calmodulin reversibly bound to multiple sites on InsP3 receptors and Ca2+ increased the binding by 190% +/- 10%; the half-maximal effect occurred when the Ca2+ concentration was 184 +/- 14 nM. In the absence of Ca2+, calmodulin caused a reversible, concentration-dependent (IC50 = 3.1 +/- 0.2 microM) inhibition of [3H]InsP3 binding by decreasing the affinity of the receptor for InsP3. This effect was similar at all Ca2+ concentrations, indicating that the site through which calmodulin inhibits InsP3 binding has similar affinities for calmodulin and Ca2+-calmodulin. Calmodulin (10 microM) inhibited the Ca2+ release from cerebellar microsomes evoked by submaximal, but not by maximal, concentrations of InsP3. Tonic inhibition of InsP3 receptors by the high concentrations of calmodulin within cerebellar Purkinje cells may account for their relative insensitivity to InsP3 and limit spontaneous activation of InsP3 receptors in the dendritic spines. Inhibition of InsP3 receptors by calmodulin at all cytosolic Ca2+ concentrations, together with the known redistribution of neuronal calmodulin evoked by protein kinases and Ca2+, suggests that calmodulin may also allow both feedback control of InsP3 receptors and integration of inputs from other signaling pathways.


Subject(s)
Calcium Channels/metabolism , Calcium/metabolism , Calmodulin/metabolism , Calmodulin/pharmacology , Cerebellum/metabolism , Microsomes/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Animals , Binding, Competitive , Brain/metabolism , Calcium/pharmacology , Calcium Channels/chemistry , Cattle , Inositol 1,4,5-Trisphosphate/metabolism , Inositol 1,4,5-Trisphosphate Receptors , Kinetics , Microsomes/drug effects , Models, Neurological , Models, Structural , Rats , Receptors, Cytoplasmic and Nuclear/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...